explore -WSS

explore

author：hotspot 2025-10-01 21:24:10 - browse：65537

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Lack of health data on LGBTQ+ people has serious consequences

WSS

Pregnant women don't need prenatal multivitamins, study concludes

A new approach to psychiatric drug development

FDA panel gives mixed vote on blood pressure devices

CDC advisory panel says seniors 'may' get RSV vaccine

First over

Complete sequence of Y chromosome published for first time

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Affirmative action in medical school literally saved lives

Change Healthcare: What is it, why does its cyberattack matter?

23andMe had bad news about my health. I wish a person had delivered it

Ozempic has benefits for kidney disease as well as diabetes

The high cost of giving birth even with insurance

Lack of health data on LGBTQ+ people has serious consequences

New air purifier tech could be key to improving indoor air quality

Psilocybin's anti

Medicare details structure of new drug price negotiation program

Complete sequence of Y chromosome published for first time

entertainment

Fetal cell organoids grown from amniotic fluid, study finds

Diversity in medical illustrations gets boost from Chidiebere Ibe

Families look for replacement for GSK asthma drug Flovent

As pharma fights Medicare drug negotiation, hospitals, docs silent

How to make Best Hospitals ratings actually useful for patients

Ozempic has benefits for kidney disease as well as diabetes

focus

focus

hotspot

focus